Preclinical Imaging (In-VIVO) - Global Strategic Business Report

The global market for Preclinical Imaging (In-VIVO) was estimated at US$1.1 Billion in 2024 and is projected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Preclinical Imaging (In-VIVO) market.

Global Preclinical Imaging (In-VIVO) Market - Key Trends and Drivers Summarized

Preclinical Imaging (In-VIVO): Advancing Biomedical Research

Preclinical imaging (in-vivo) refers to the use of advanced imaging techniques to visualize and study biological processes in live animal models, primarily for biomedical research purposes. This imaging is conducted before clinical trials in humans, helping researchers understand disease mechanisms, evaluate the efficacy of new drugs, and monitor treatment effects in real-time. Common imaging modalities used in preclinical research include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging techniques such as bioluminescence and fluorescence imaging. The importance of preclinical imaging lies in its ability to provide detailed insights into the biological processes underlying health and disease, enabling researchers to make informed decisions in drug development and other areas of biomedical research. By allowing non-invasive monitoring of disease progression and treatment response, preclinical imaging plays a crucial role in the advancement of medical science.

How Are Technological Advancements Enhancing Preclinical Imaging (In-VIVO)?

Technological advancements have significantly improved the capabilities of preclinical imaging, enhancing both the resolution and functionality of imaging modalities. Innovations in imaging hardware, such as higher-field MRI magnets and more sensitive PET detectors, have increased the spatial and temporal resolution of images, allowing for more detailed visualization of biological processes. The development of multimodal imaging systems, which combine two or more imaging techniques (e.g., PET/CT or MRI/PET), has enabled researchers to simultaneously capture complementary data, providing a more comprehensive understanding of disease mechanisms and treatment effects. Advances in molecular imaging agents, including targeted contrast agents and radiotracers, have improved the specificity of imaging, allowing for the visualization of specific molecular pathways and cellular processes. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into image analysis has enhanced the ability to process and interpret complex imaging data, facilitating more accurate and efficient research outcomes. These technological improvements have expanded the applications and impact of preclinical imaging, making it an indispensable tool in biomedical research.

What Are the Key Applications and Benefits of Preclinical Imaging (In-VIVO)?

Preclinical imaging (in-vivo) is used in various research areas, offering numerous benefits that advance the understanding of disease and the development of new treatments. In oncology research, preclinical imaging allows for the non-invasive tracking of tumor growth and metastasis, helping researchers evaluate the effectiveness of cancer therapies in real-time. In neuroscience, imaging techniques such as MRI and PET are used to study brain structure and function, providing insights into neurological disorders such as Alzheimer`s disease and Parkinson`s disease. Cardiovascular research benefits from preclinical imaging through the visualization of heart and blood vessel function, aiding in the study of heart disease and the development of new cardiovascular drugs. Additionally, preclinical imaging is used in pharmacokinetics and pharmacodynamics studies to monitor the distribution and action of drugs within the body. The primary benefits of preclinical imaging include the ability to conduct non-invasive, real-time monitoring of biological processes, the reduction of animal use through longitudinal studies, and the generation of high-resolution data that can inform clinical research. These advantages make preclinical imaging a critical component of modern biomedical research.

What Factors Are Driving the Growth in the Preclinical Imaging (In-VIVO) Market?

The growth in the preclinical imaging (in-vivo) market is driven by several factors. The increasing demand for more precise and non-invasive methods to study disease mechanisms and evaluate drug efficacy is a significant driver, as preclinical imaging provides critical insights that inform clinical research and drug development. Technological advancements that enhance the resolution, sensitivity, and functionality of imaging modalities are also propelling market growth. The expansion of the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine, is contributing to the increased demand for preclinical imaging tools. Additionally, the growing emphasis on reducing animal use in research, coupled with the ability of preclinical imaging to enable longitudinal studies in the same animals, is further boosting market adoption. The integration of advanced data analysis techniques, including AI and machine learning, is enhancing the utility of preclinical imaging, driving its continued growth. These factors, combined with the ongoing innovation in imaging technologies, are driving the sustained growth of the preclinical imaging (in-vivo) market.

SCOPE OF STUDY:

The report analyzes the Preclinical Imaging (In-VIVO) market in terms of units by the following Segments, and Geographic Regions/Countries:

• Segments: Segment (Preclinical imaging modalities, Preclinical imaging reagents)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Preclinical imaging modalities segment, which is expected to reach US$900.1 Million by 2030 with a CAGR of a 5.2%. The Preclinical imaging reagents segment is also set to grow at 4.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $295.1 Million in 2024, and China, forecasted to grow at an impressive 4.6% CAGR to reach $225.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Preclinical Imaging (In-VIVO) Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Preclinical Imaging (In-VIVO) Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Preclinical Imaging (In-VIVO) Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Aspect Imaging Ltd., Bruker Corp., Idex Health & Science LLC, Mauna Kea Technologies, Mediso Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 38 companies featured in this Preclinical Imaging (In-VIVO) market report include:

• Aspect Imaging Ltd.
• Bruker Corp.
• Idex Health & Science LLC
• Mauna Kea Technologies
• Mediso Ltd.
• Milabs B.V.
• Miltenyi Biotech GmbH
• MR Solutions
• New England Biolabs
• PerkinElmer, Inc.
• Siemens A.G.
• Trifoil Imaging, Inc.
• FujiFilm VisualSonics, Inc.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.